Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Announcements and Reports
Home
>
Announcements and Reports
>
ASX Announcements
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
31-May-2023
Key to Corporate Governance Disclosures
30-May-2023
2023 Corporate Governance Statement
30-May-2023
Annual Report to Shareholders
29-May-2023
AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
23-May-2023
Grant to collaborate with CSIRO Supplementary Announcement
22-May-2023
Amplia receives grant to collaborate with CSIRO
9-May-2023
ACCENT Trial Recruitment Progress
26-Apr-2023
Quarterly Activities and Cashflow Reports - March 23 Qtr
19-Apr-2023
First Patient Recruited to Cohort 3 of ACCENT Trial
11-Apr-2023
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
1
2
Next
